ArticleCurrent opinion in biomedical engineering2025
Mechanosensing Pathways in the Progression of Pulmonary Fibrosis.
Article in Current opinion in biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modeling ventilation heterogeneity in lung fibrosis.Medical & biological engineering & computing · 2026Article
- An hiPSC-derived multi-lineage lung model exhibiting proximal-distal epithelial features for modeling pulmonary fibrosis.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Fibrotic diseases are characterized by the excess production of extracellular matrix components that leads to changes in tissue mechanics and function. Mechanosensing altered during the onset of pulmonary fibrosis is hypothesized to form a positive-feedback loop that contributes to the progression of the disease. However, the exact mechanism(s) leading to fibrotic tissue remodeling as opposed to homeostatic tissue remodeling remains unknown. The development of innovative laboratory models of pulmonary fibrosis has facilitated mechanistic studies of pathogenic mechanosensing and identified new anti-fibrotic candidates. This brief review will cover recent (< 5 years) publications that explore mechanotransduction pathways contributing to the development of pulmonary fibrosis and innovative laboratory models that can advance the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.